ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: L11 • ACR Convergence 2020

    Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Atul Deodhar1, Paula Sliwinska-Stanczyk2, Huji Xu3, Xenofon Baraliakos4, Lianne Gensler5, Dona Fleishaker6, Lisy Wang6, Joseph Wu6, Sujatha Menon6, Cunshan Wang6, Oluwaseyi Dina7, Lara Fallon8, Keith S Kanik6 and Désirée van der Heijde9, 1Oregon Health & Science University, Portland, OR, 2Reumatika Centrum Reumatologii, Warszawa, Poland, 3Shanghai Changzheng Hospital, Shanghai, China (People's Republic), 4Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany, 5University of California San Francisco, San Francisco, CA, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, New York, NY, 8Pfizer Inc, Montreal, QC, Canada, 9Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for the treatment of adult patients (pts) with AS.Methods: This Phase 3, randomized, double-blind…
  • Abstract Number: 0201 • ACR Convergence 2020

    A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study of SHR0302 versus Placebo in Chinese Subjects with Moderate to Severe Active Rheumatoid Arthritis (RA)

    Xiaofeng Zeng1, Ying Jiang2, Ying Yang3 and Hanying Li4, 1Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), 2Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China (People's Republic), 3Jiangsu Hengrui Medicine Co., Ltd, Guangzhou, China (People's Republic), 4Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China (People's Republic)

    Background/Purpose: Proinflammatory cytokine activation of JAK/STAT signal pathway is critical in the pathogenesis and progression of RA. SHR0302, a potent and selective inhibitor of JAK1,…
  • Abstract Number: 0236 • ACR Convergence 2020

    Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial

    Rene Westhovens1, DaeHyun Yoo2, Piotr Wiland3, Marek Zawadzki4, Delina Ivanova5, Alfredo Berrocal Kasay6, Elias Chalouhi7, Eva Balázs8, SangJoon Lee9, SungHyun Kim9, JeeHye Suh9, NooRi Han9 and HoJae Lee9, 1University Hospitals Leuven, Belgium, Leuven, Belgium, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 3Medical Univeristy, Wroclaw, Poland, 4Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, 5Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, 6ABK Reuma SRL, LIMA, Peru, 7Clinica Internacional Sede Lima, Lima, Peru, 8Dr. Bugyi István Hospital, Szentes, Hungary, 9Celltrion, Inc., Incheon, Republic of Korea

    Background/Purpose: The subcutaneous (SC) formulation of CT-P13 received marketing authorization for RA from the EMA by demonstrating non-inferiority compared to CT-P13 intravenous for efficacy in…
  • Abstract Number: 0515 • ACR Convergence 2020

    A Proof of Concept Study to Assess the Efficacy of Tocilizumab in Combination with Ultra-Short Glucocorticoid Administration to Treat Newly Diagnosed Giant Cell Arteritis – a 24 Week Analysis

    Lisa Christ1, Luca Seitz1, Lukas Buetikofer2, Godehard Scholz1, Adela-Cristina Sarbu1, Jennifer Amsler1, Florian Kollert1, Stephan Reichenbach1 and Peter Villiger1, 1Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, 2Clinical Trials Unit, University of Bern, Bern, Switzerland, Bern, Switzerland

    Background/Purpose: Two randomized controlled trials [Villiger et al. Lancet 2016; Stone et al. NEJM 2017] demonstrated a glucocorticoid (GC)-sparing effect of tocilizumab (TCZ) of at…
  • Abstract Number: 0860 • ACR Convergence 2020

    PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE

    Paul Dunford1, Gail Comer1, Ralph Raymond1, Donald Jung1, Paul Moore2, Francisco Leon1 and Joan Merrill3, 1Provention Bio, Oldwick, NJ, 2MacroGenics, Rockville, MD, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: B-cell targeted therapeutics have proven efficacious in the treatment of autoimmune disorders.  A desired improvement in efficacy and safety necessitate the development of alternate,…
  • Abstract Number: 1094 • ACR Convergence 2020

    Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis

    Julie Paik1, Jemima Albayda1, Eleni Tiniakou1, Grazyna Purwin1, Andrew Koenig2 and Lisa Christopher-Stine1, 1Johns Hopkins University, Baltimore, MD, 2Pfizer Inc, New York City, NY

    Background/Purpose: Tofacitinib is a pan-JAK inhibitor that demonstrated safety and efficacy in a 12 week open label trial of 10 subjects with refractory dermatomyositis (NCT03002649).…
  • Abstract Number: 1482 • ACR Convergence 2020

    Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis

    John Carrino1, Timothy McAlindon2, Eric Vignon3, Mark Brown4, Aimee Burr4, Robert Fountaine4, Glenn Pixton5, Lars Viktrup6, Christine West7 and Kenneth Verburg8, 1Hospital for Special Surgery, Hackensack, NJ, 2Tufts Medical Center, Boston, MA, 3Université Claude Bernard Lyon 1, Pierre Benite, France, 4Pfizer Inc., Groton, CT, 5Pfizer Inc., Morrisville, NC, 6Eli Lilly and Company, Indianapolis, IN, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Groton

    Background/Purpose: Tanezumab, a monoclonal antibody that inhibits nerve growth factor, has been shown effective in the management of osteoarthritis (OA) pain.1,2 Due to the potential…
  • Abstract Number: 1843 • ACR Convergence 2020

    Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids

    Ellen M Ginzler1, Joshua Kaplan2, Laura Lisk3, Ray Federico4, Neil Solomons5 and Robert Huizinga5, 1SUNY Downstate Health Sciences University, Brooklyn, 2Rutgers University, New Brunswick, NJ, 3Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, 4Aurinia Pharmaceuticals, Inc., Victoria, Canada, 5Aurinia Pharmaceuticals, Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for…
  • Abstract Number: 0204 • ACR Convergence 2020

    Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects

    KyungSang Yu1, InJin Jang1, HyeongSeok Lim2, JangHee Hong3, MinGul Kim4, MinKyu Park5, Anhye Kim6, MinSoo Park7, JaeYong Chung8, JongLyul Ghim9, SeungHwan Lee1, SeokKyu Yoon2, InSun Kwon3, Daniel Furst*10, Edward C Keystone11, SangJoon Lee12, SungHyun Kim12, YunJu Bae12, JungBin Cha13, HyeJin Kang13 and Jonathan Kay14, 1Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea, 2College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Republic of Korea, 3Chungnam National University Hospital, Daejeon, Republic of Korea, 4College of Medicine, Jeonbuk National University, Jeonbuk, Republic of Korea, 5Chungbuk National University Hospital, Cheongju, Republic of Korea, 6CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea, 7Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, 8Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 9Inje University Busan Paik Hospital, Busan, Republic of Korea, 10Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, 11Mount Sinai Hospital, Toronto, ON, Canada, 12Celltrion, Inc., Incheon, Republic of Korea, 13Celltion, Inc., Incheon, Republic of Korea, 14University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: CT-P17 was developed as the first biosimilar of the high concentration (100 mg/mL), citrate-free formulation of reference adalimumab. The purpose of this study was…
  • Abstract Number: 0237 • ACR Convergence 2020

    Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis

    Stanley Cohen1, Ronald F Van Vollenhoven2, Jeffrey Curtis3, Leonard Calabrese4, Cristiano AF Zerbini5, Yoshiya Tanaka6, Louis Bessette7, Casey Schlacher8, Tim Shaw9, John Liu9, Jeffrey Enejosa9, Yanna Song10 and Gerd Burmester11, 1Metroplex Clinical Research Center, Dallas, TX, 2Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Cleveland Clinic, Cleveland, OH, 5Centro Paulista de Investigacao Clinica (CEPIC), Sao Paulo, Brazil, 6The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 7Laval University, Quebec, Canada, 8AbbVie Inc., Lake Forest, IL, 9AbbVie Inc., North Chicago, IL, 10AbbVie Inc., North Chicago,, IL, 11Charité University Hospital Berlin, Berlin, Germany

    Background/Purpose: The safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, was evaluated in the phase 3 SELECT clinical program, which included 5 randomized,…
  • Abstract Number: 0546 • ACR Convergence 2020

    Stepping up for Inflammatory Arthritis (SUFIA): A Pilot Trial to Test Behavioral Economics Strategy to Increase Physical Activity in Inflammatory Arthritis

    Alexis Ogdie1, Kathleen Bush1, Michael George1, Mitesh Patel1, William Nowell2, Kelly Gavigan3, Jeffrey Curtis4 and Joshua Baker5, 1University of Pennsylvania, Philadelphia, PA, 2Global Healthy Living Foundation, New York City, NY, 3Global Healthy Living Foundation, Upper Nyack, NY, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Regular physical activity may have benefits for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but patients with active disease are often reluctant…
  • Abstract Number: 0862 • ACR Convergence 2020

    Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE

    Teun van Gelder1, Robert Huizinga2, Neil Solomons2 and Laura Lisk3, 1Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc., Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
  • Abstract Number: 1201 • ACR Convergence 2020

    Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials

    Peter Taylor1, Arthur Kavanaugh2, Peter Nash3, Janet Pope4, Beatrix Bartok5, Ken Hasegawa5, Shangbang Rao5, Sander Strengholt6 and Rene Westhovens7, 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, 3School of Medicine Griffith University, Brisbane, Queensland, Australia, 4Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 5Gilead Sciences, Inc., Foster City, CA, 6Galapagos BV, Leiden, Netherlands, 7University Hospitals Leuven, Belgium, Leuven, Belgium

    Background/Purpose: RA patients (pts) often suffer substantial pain despite ongoing treatment (tx) and regard pain control as a top tx goal. Filgotinib (FIL)—a potent, oral…
  • Abstract Number: 1490 • ACR Convergence 2020

    Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials

    Camila Pinto1, Joana Barroso2 and Thomas Schnitzer3, 1Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Despite the known high inter- and intra-patient variability in analgesic responses in chronic pain, most interventional pain studies rely on single time point pain…
  • Abstract Number: 1847 • ACR Convergence 2020

    Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus

    Hope Rainey1, Kristy Bell1, Violeta Rus2, Daniel Wallace3, Claire Dykas1, Mary Mora1, Maggy Comberg1 and Peter Lipsky1, 1AMPEL BioSolutions LLC., Charlottesville, VA, 2University of Maryland School of Medicine, Baltimore, MD, 3Cedars-Sinai Medical Center/UCLA, Los Angeles, CA

    Background/Purpose: Morning stiffness and fatigue are common symptoms in patients with SLE. Increased cytokines and disturbed sleep patterns may contribute to morning symptoms and fatigue…
  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology